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Objectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor
(EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with
cetuximab.
Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients
with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages
(III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003
and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A,
FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase
chain reaction-restriction fragment length polymorphism methods.
Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A sig-
nificant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6
(rs61764370) variant (p < 0.05); carriers of the G allele (genotypes TG + GG) in the dominant model were
observed to have a decreased susceptibility of developing dry skin (OR = 0.287 [95%CI = 0.119–0.695]).
Carriers of the A (GA + AA) allele for EGFR (rs2227983) showed a decreased risk of suffering from pruritus
(OR = 0.345 [0.124–0.958]). Similarly, KRAS (rs1801274) was related with lower global cetuximab-
related toxicity (OR = 0.266 [0.114–0.622]).
Conclusion: This pilot study provides preliminary evidence supporting genetic variation of EGFR
(rs2227983), KRAS (rs61764370) and FCGR2A (rs180127) as useful biomarkers for predicting reduced
skin toxicity in HNSCC patients treated with a cetuximab-based therapy. Alternative therapeutic options
should be explored for these patients.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Head and Neck Carcinoma (HNC) includes a large number of
tumors located in different anatomical regions of the upper aerodi-
gestive tract. More than 90% of HNC tumors have a squamous cell
histology [1] and are classified as head and neck squamous cell car-
cinoma (HNSCC), the sixth most common cancer worldwide [2].
Tobacco use and alcohol consumption are the most relevant
J. Fernández-Mateos et al. / Oral Oncology 63 (2016) 38–43 39etiological factors showing additive effect [3,4]. Nevertheless, in
the last decades viral infection by the Epstein-Barr virus (EBV) or
human papillomavirus (HPV) have been suggested as a cause of
nasopharyngeal and oropharyngeal cancer, respectively. These
EBV or HPV positive tumors appear to be clinically and molecularly
different from negative virus carcinomas [5]. In addition, genetic
variation in the germinal cell line has been found to modify the risk
of disease and patient survival [3,6]. Despite their common squa-
mous origin, the prognosis of these tumors primarily depends on
their size and the presence of cervical lymph node and/or distant
metastasis. Treatment options for HNSCC includes surgery, radio-
therapy, platinum-based chemotherapy and targeted therapeutic
agents [7]. However, these patients usually achieve an advanced-
staged diagnosis that compromises first line response rates [8].
The epidermal growth factor receptor (EGFR) is a transmem-
brane tyrosine kinase receptor that plays a fundamental role in sig-
nal transduction pathways involved in DNA repair, tumor cell
survival (PI3K-PTEN-AKT pathway), cell proliferation (RAS-RAF-
MAPK pathway) and metastasis [9]. More than 95% of HNSCC
patients have EGFR overexpression and it has been associated with
a decreased response to therapy, reduced disease-free and overall
survival (OS) [5]. Due to its prevalence and crucial role in patho-
genesis, targeting EGFR has become a rational approach for HNSCC
treatment.
Cetuximab, a chimeric mouse/human IgG1-type monoclonal
antibody (MAb), is an anti-EGFR therapy approved for the treat-
ment of locally advanced HNSCC [10,11]. Cetuximab in combina-
tion with radiotherapy or platinum-containing chemotherapy
regimens has already shown significant improvement of treatment
outcomes in metastatic and relapsed disease [7,10–15].
Cetuximab can cause antitumor effects through three different
mechanisms: firstly, it specifically binds to the extracellular
domain III of the EGFR as a competitive inhibitor of the natural
EGF ligands and downstream pathway activation [16]. Secondly,
cetuximab decreases the number of EGFRs in the tumor cell
membrane though EGFR-cetuximab complex endocytosis and
destruction by lysosomes. Thirdly, cetuximab can induce
antibody-dependent cell-mediated cytotoxicity (ADCC) [17]
through the interaction of the Fc region of the monoclonal anti-
body with the Fc gamma receptor (FcgR) carried by macrophages
and natural killer cells [18,19].
Clearly, clinical benefit and low toxicity with EGFR-targeting
antibodies seems to be restricted to a particular subgroup of
HNSCC patients [20]. Although critically required for managing
the high cost of this type of therapy and their anticipated integra-
tion in other clinical regimens, no validated predictive factors are
currently available to improve treatment decision making [20].
Thus, it appears necessary to better define the subpopulation of
patients who truly benefits from cetuximab treatment and its tox-
icity. Single nucleotide polymorphisms (SNP) may affect pharma-
codynamics of anti-EGFR therapies introducing inter-patient
variability at the level of the EGFR target itself, the downstream
cascade, as well as at the ADCC. It has been reported that two SNPs
located in the coding region of the FcgR have been associated with
differences in the response and toxicity to cetuximab: a histidine
(H)/arginine(R) polymorphism at position 131 of FCGR2A
(rs1801274) and a valine(V)/phenylalanine(F) polymorphism at
position 158 in FCGR3A (rs396991) [18,19,21,22]. At least three
functional EGFR variants have been associated with EGFR regula-
tion: rs2227983 [23], rs28384375 and rs17336639 [24,25] coding
for amino acids located at the extracellular domain.
Moreover, some downstream effectors of EGFR signaling such
as cyclin-D1 gene (CCDN1) may also plays a role in modulating
cetuximab activity, given that CCND1 A870G (rs603965) polymor-
phism is positively correlated with HNSCC patient survival [26].
Finally, microRNA (miRNAs) – small non-coding RNAs able tosuppress translation through their binding to the gene 30-
untanslated region (UTR) or inducing mRNA degradation – [27],
can regulate KRAS activity, i.e. let-7 miRNA. A polymorphism in
LCS6 (rs617764370) modifies let-7 binding affinity and it was asso-
ciated with increased KRAS expression in an in vitro model, reduc-
ing survival in oral cancer and improving patient response to
cetuximab [28].
Several studies have also found a relationship between skin tox-
icity, the most relevant cetuximab-related secondary effect [10,29],
and a better response [30–32].
Therefore, the main objective of this study was to examine the
possible associations between polymorphisms at genes coding for
EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 and toxicity in
HNSCC patients treated with cetuximab.Materials and methods
Patients and treatment
A total of 110 patients with histologically-confirmed HPV-
negative HNSCC were enrolled in a multicenter retrospective
observational pilot study coordinated by the Medical Oncology
Service of the University Hospital of Salamanca, Spain. All patients
included in the study were diagnosed with locally advanced stages
(III-IVA-B) and treated with chemotherapy and radiotherapy plus
cetuximab between 2003 and 2013. The study was carried out after
ethics committee approval and collection of informed consent
from each patient. Patient tumor characteristics (location and
stage) and data related to treatment (radiotherapy, chemotherapy
and EGFR targeted therapy) and specific toxicity were compiled in
a case report form (CRF) questionnaire by a medical oncologist.
The inclusion criterion was patients with a confirmed oral cav-
ity, larynx, hypopharynx or oropharynx HNSCC diagnosis and who
were treated with cetuximab. Cetuximab alone (n = 2) or with
chemotherapy (n = 6), radiotherapy (n = 21), or radiochemother-
apy (n = 81) was administered at an initial dose of 400 mg/m2 fol-
lowed by subsequent weekly dose of 250 mg/m2 until disease
progression or severe toxicity. Toxicity was recorded according to
National Cancer Institute Common Toxicity Criteria (NCI-CTCAE),
version 3.0. Exclusion criteria were uncertain or debatable diagno-
sis, benign tumors, and HPV-positive HNSCC confirmed by either
PCR or immunohistochemistry.DNA isolation and polymorphisms genotyping
Samples were obtained by venipuncture of a peripheral vein.
DNA was extracted from leukocytes by phenol-chloroform extrac-
tion. Genetic analysis was performed using TaqMan Allelic Dis-
crimination Assay (Applied Biosystems) for SNPs for which
TaqMan probes were designed (Table 1). In these cases, 40 ng/ll
of each sample were added to 6.25 ll of Taqman Universal PCR
Master Mix and 12.5 ll of reaction was combined with specific for-
ward and reverse primers, and allele-specific VIC (allele 1) and
FAM (allele 2) labeled probes. The assay was performed in a 96
well plate and the detection was measured in the Applied Biosys-
tems Step One Plus instrument where the thermal cycling and
detection was carried out. Negative and positive controls were
always added [33].
The CCDND1 A870G polymorphism (rs603965) was analyzed by
polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method. The forward primer was: 50-GTGAAGTT
CATTTCCAATCCGC-30 and the reverse: 50-GGGACATCACCCTCACT
TAC-30. Digestion was made by the restriction enzyme ScrFI. The
PCR products were run on 3% Syber-safe stained agarose gel and
visualized under UV light [34].
Table 1
Polymorphisms analyzed by TaqMan probes in HNSCC patients.
SNP RefSNP Location Context sequence [VIC/FAM]
EGFR R521K rs2227983 Chr.7: 55161562 GAGGGCTGCTGGGGCCCGGAGCCCA[A/G]GGACTGCGTCTCTTGCCGGAATGTC
EGFR V592A rs28384375 Chr.7: 55233025 CACTACATTGACGGCCCCCACTGCG[C/T]CAAGACCTGCCCGGCAGGAGTCATG
EGFR P266R rs17336639 Chr.7: 55154060 GCCACGTGCAAGGACACCTGCCCCC[C/G]ACTCATGCTCTACAACCCCACCACG
KRAS-LCS6 rs61764370 Chr.12:25207290 F:50-GCCAGGCTGGTCTCGAA-30
R:50-CTGAATAAATGAGTTCTGCAAAACAGGTT-30
CTCAAGTGAT[T/G]CACCAC
FCGR2A H131R rs1801274 Chr.1: 161509955 AATGGAAAATCCCAGAAATTCTCCC[A/G]TTTGGATCCCACCTTCTCCATCCCA
FCGR3A V18F rs396991 Chr.1: 161544752 TCTGAAGACACATTTTTACTCCCAA[C/A]AAGCCCCCTGCAGAAGTAGGAGCCG
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Statistical analysis compared categorical parameters and poly-
morphism status by the Chi-square test. P-values were considered
statistically significant when p < 0.05. Significant variables were
included in the logistic regression analysis and size effects were
indicated by odds ratio (OR) with their 95% confidence interval
(95% CI). Dose and toxicity influence was analyzed by a Mann-
Whitney U test due to the non-parametric distribution of the vari-
ables. Secondary endpoint was cetuximab-related toxicity. All
these tests were conducted using SPSS software 21.0 version for
Windows (SPSS Inc., Chicago).
Toxicity was graded between 0 = absence and grade 4 = severe,
grouped as low (12) or high (3–4) grade, and classified as ‘‘pre-
sent” or ‘‘absent”. The term global toxicity was applied if the
patients presented some grade of toxicity to the treatment.Results
A total of 110 locally advanced HNSCC patients were analyzed.
Most of the patients included in the study were men with a median
age of diagnosis of 59.63 years old. Regarding tumor characteris-
tics, the most common were laryngeal neoplasias (45.5%), followed
by pharyngeal (41.8%) and oral cavity (12.7%); the majority of
tumors were stage IV (70.0%), followed by stage III (30.0%)
(Table 2). As for the therapy received in combination with cetux-
imab, 6 (5.5%) patients were treated with chemotherapy, 21
(19.1%) with radiotherapy and 81 (73.6%) with radiochemotherapy
(Table 3). Statistical association was not found in the comparison
between patients undergoing radiochemotherapy and cetuximab
versus the remaining therapies (p > .05), thus indicating that the
toxicity between the two groups was likely produced by the cetux-
imab treatment itself (Table 3).
Regarding the specific toxicity of cetuximab, 55.5% of HNSCC
patients presented acneiform rash, 46.4% of them in low grade;
while dry skin was present in 45.5% of cases and pruritus in
20.9% (Table 4). Despite a variation in the number of cetuximab
cycles, mean 10.54 ± 15.04, no statistically-significant relationship
was observed between accumulated doses and toxicity in theTable 2
Characteristics of HNSCC patients.
N %
Sex Male 100 90.9
Female 10 9.1
Location Larynx 50 45.5
Oropharynx 30 27.3
Hypopharynx 16 14.5
Oral cavity 14 12.7
Stage III 33 30.0
IVA 65 59.1
IVB 12 10.9Mann-Whitney U test (dry skin p = 0.116, pruritus p = 0.787 and
rash p = 0.284).
The genotype distribution of EGFR rs2227983, rs28384375 and
rs17336639, FCGR2A rs1801274, FCGR3A rs396991, KRAS-LCS6
rs61764370, and CCDN1 rs603965 polymorphisms are shown in
Table 5. EGFR polymorphisms rs28384375 and rs17336639 had
only the major allele variant in our sample (Table 5), though in
the European population rs28384375 has been described as having
a distribution of 84% CC, 14.2% CT and 1.2% TT, and for rs17336639:
98.9% CC and 1.1% CG. Thus they were not included in subsequent
analyses. The remaining SNPs were analyzed according to the most
common toxicity produced by monoclonal antibodies treatment:
dry skin, pruritus and acneiform rash.
Statistical analyses using the Chi-square test showed significant
association between dry skin and the KRAS-LCS6 (rs61764370)
variant (p < 0.05). Moreover, global cetuximab-related toxicity
was also associated with this polymorphism, and may be due to
the association with dry skin toxicity (Table 6). These results
showed that being a carrier of the G allele (genotypes TG + GG)
of the KRAS-LCS6 rs61764370 polymorphism in the dominant
model decreases the susceptibility to develop dry skin after cetux-
imab treatment (p = 0.006, OR = 0.287 [95% CI = 0.119–0.695])
(Table 7). Although not significant, a tendency in the recessive
model of FCGR2A rs1801274 where the TT genotype was close to
being associated with a decreased risk of dry skin, p = 0.051
OR = 0.380 (0.144–1.003), was observed (Table 7). Secondly, the
EGFR rs2227983 polymorphism showed an association with pruri-
tus toxicity. Carriers of GA + AA genotypes were found to have a
decreased risk of suffering from pruritus: p = 0.041, OR = 0.345
(0.124–0.958) (Table 7). Regarding patients with global
cetuximab-related toxicity, the KRAS (rs61764370) variant was
less susceptible to global toxicity related to MAb treatment
(p = 0.002, OR = 0.266 [95% CI = 0.114–0.622]) (Table 7).Discussion
Cetuximab combined with radiotherapy or chemotherapy
improves locoregional control and survival in HNC patients, but
only a subset of all patients are able to benefit from anti-EGFR
monoclonal antibodies [35]. Thus, the detection of predictive
biomarkers and of beneficial patient profiles is crucial. Several
studies have correlated clinical outcome and toxicity to IgG1
cetuximab treatment with polymorphisms in the EGFR pathway
with conflicting results [18,19,21,22,26,28]. In this proof of concept
study we evaluated the possibility of an association between
cetuximab toxicity and polymorphism distribution in the EGFR
pathway, looking for predictive biomarkers of toxicity.
Skin toxicity is a frequent side effect of EGFR targeting agents
and it correlates with a better treatment efficacy [32]. It causes
some cutaneous changes such as acneiform rash, dry skin and itch-
ing. Although these toxicities can negatively impact on the patient
quality of life, the identification of new biomarkers may contribute
Table 3
Treatment and cetuximab-related toxicity.*
Acneiform Rash Dry skin Pruritus Global toxicity
N % N % N % N % N %
Cetuximab alone 2 1.8 19 65.5 15 51.7 4 13.8 22 75.9
Cetuximab + Radiotherapy 21 19.1
Cetuximab + Chemotherapy 6 5.5
Cetuximab + Radiochemotherapy 81 73.6 42 51.9 35 43.2 19 23.5 51 63.0
* The data represents only patients who developed toxicity. A Chi-Square test was performed between patients undergoing radiochemotherapy plus cetuximab versus the
remaining therapies and there were not statistical differences between both groups (p > .05) (data not shown).
Table 4
Toxicity caused by cetuximab therapy, clustered by low (12) and high (3–4) grade.
Acneiform rash Dry skin Pruritus
N % N % N %
Absence 49 44.5 60 54.5 87 79.1
G1-2 51 46.4 41 37.3 22 20.0
G3-4 10 9.1 9 8.2 1 0.9
Table 5
Distribution of polymorphism genotypes in this sample.
SNP Genotype frequency
EGFR rs2227983 GG GA AA
60 (54.5%) 43 (39.1%) 7 (6.4%)
EGFR rs28384375 CC CT TT
110 (100%) 0 (0%) 0 (0%)
EGFR rs17336639 CC CG GG
110 (100%) 0 (0%) 0 (0%)
FCGR2A rs1801274 CC CT TT
17 (15.5%) 68 (61.8%) 25 (22.7%)
FCGR3A rs396991 TT TG GG
39 (35.5%) 55 (50.0%) 16 (14.5%)
KRAS-LCS6 rs61764370 TT TG GG
75 (68.2%) 31 (28.2%) 4 (3.6%)
CCDN1 rs603965 AA AG GG
29 (26.4%) 57 (51.8%) 24 (21.8%)
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thus have a better response to treatment. EGFR is normally found
in keratinocytes of the epidermis, follicular epithelium and sweat
glands. This receptor has an important function in skin homeosta-
sis and its inhibition drives to an abnormal proliferation and differ-
entiation of the epithelium [36].
In this study no relationship between genotype distribution of
EGFR rs28384375, rs17336639, FCGR2A rs1801274, FCGR3A
rs39661 and CCDN1 rs603965 gene polymorphisms and cetuximab
toxicity was observed for this patient population. However, an
association between EGFR rs2227983 and pruritus development
after cetuximab treatment was observed. The EGFR SNP
rs2227983 G > A in exon 13 produces a change of arginine to lysine
in the position 521 (R521K). Previous reports have noted that
carriers of the A allele (AA or GA) were associated with a lowerTable 6
P-values of different polymorphism selected comparing grade of toxicity (as shown in Tab
Rash acneiforme Dry s
Polymorphism Gene Grade Yes/no Grad
rs2227983 EGFR 0.808 0.863 0.917
rs1801274 FCGR2A 0.474 0.410 0.101
rs396991 FCGR3A 0.285 0.274 0.497
rs61764370 KRAS 0.389 0.135 0.039
rs603965 CCDN1 0.437 0.512 0.974
Statistically significant results in bold.incidence of skin rash compared with the GG genotype in advanced
HNC [32]. In this study AA + GA was associated with a lower risk of
developing pruritus (p = 0.041; OR = 0.345 [0.124–0.958]).
Although this relationship remains unclear, this SNP is located in
the extracellular region, where the monoclonal antibody and the
EGF ligand interact, so structural changes at codon 521 could pro-
voke a modification of EGF interaction with the receptor. In conclu-
sion, AA genotype could be related with decreased cetuximab
binding, low effectiveness of the monoclonal antibody and less tox-
icity, also clearly related with a lower response [32].
In this study, KRAS rs617764370 SNP was observed to be asso-
ciated with lower dry skin and global cetuximab-related toxicity.
MicroRNA SNPs are arising as relevant molecular markers in per-
sonalized medicine. The KRAS-LCS6 variant has a functional
impact on let-7 miRNA joining to 30-UTR of KRAS gene [28], caus-
ing less inhibition and an increased KRAS expression [28]. KRAS, a
downstream EGFR effector, is involved in cell proliferation and
maintain skin homeostasis [36]. KRAS rs61764370 has been also
associated with reduced OS in oral cancer [28]. Our results show
a lower risk of developing skin or global toxicity in variant carri-
ers probably due to a higher KRAS activity. If early skin toxicity
predicts better outcome and response after cetuximab treatment
[30,32], these results indicate that lower toxicity is related with
worse response and tumor progression after cetuximab treat-
ment, associated to higher KRAS expression. Moreover, EGFR inhi-
bition has been previously associated with higher grade of skin
toxicity, due the lower activity of downstream signal, inducing
inflammatory response [36]. As KRAS is an important effector
on the pathway that maintains skin homeostasis, the increase of
KRAS expression due to variant rs61764370 could activate impor-
tant transcription factors to keep skin homeostasis and reducing
skin toxicity [36].le 3) and the presence or absence of the event.
kin Pruritus Global toxicity
e Yes/no Grade Yes/no Yes/no
1.000 0.172 0.079 0.853
0.051 0.620 0.446 0.138
0.185 0.646 0.694 0.292
0.013 0.657 0.411 0.003
0.819 0.357 0.147 0.688
Table 7
Distribution of genotypes associated to skin/global toxicity.
SNP Genotype Patients with toxicity Patients without toxicity p-Value OR (95% IC)
KRAS rs61764370 in association with dry skin TT 41 (82.0%) 34 (56.7%) / 1.00
TG 8 (16.0%) 23 (38.3%) 0.008 0.288 (0.114–0.727)
GG 1 (2.0%) 3 (5.0%) 0.275 0.276 (0.027–2.780)
TT + TG 49 (98.0%) 57 (95.0%) / 1.00
GG 1 (2.0%) 3 (5.0%) 0.419 0.388 (0.039–3.849)
TT 41 (82.0%) 34 (56.7%) / 1.00
TG + GG 9 (18.0%) 26 (43.3%) 0.006 0.287 (0.119–0.695)
FCGR2A rs1801274 in association with dry skin CC 6 (12.0%) 11 (18.3%) / 1.00
CT 37 (74.0%) 31 (51.7%) 0.164 2.188 (0.726–6.595)
TT 7 (14.0%) 18 (30.0%) 0.616 0.713 (0.190–2.678)
CC + CT 43 (86.0%) 42 (70.0%) / 1.00
TT 7 (14.0%) 18 (30.0%) 0.051 0.380 (0.144–1.003)
CC 6 (12.0%) 11 (18.3%) / 1.00
CT + TT 44 (88.0%) 49 (81.7%) 0.363 1.646 (0.562–4.823)
EGFR rs2227983 in association with pruritus toxicity GG 17 (73.9%) 43 (49.4%) / 1.00
GA 6 (26.1%) 37 (42.6%) 0.090 0.410 (0.147–1.148)
AA 0 (0.0%) 7 (8.0%) 0.832 0.999 (0.000-)
GG + GA 23 (100.0%) 80 (92.0%) / 1.00
AA 0 (0.0%) 7 (8.0%) 0.999 0.000 (0.000-)
GG 17 (73.9%) 43 (49.4%) / 1.00
GA + AA 6 (26.1%) 44 (50.6%) 0.041 0.345 (0.124–0.958)
KRAS rs61764370 in association with global toxicity TT 60 (77.9%) 24 (50.0%) / 1.00
TG 16 (20.8%) 21 (43.8%) 0.007 0.296 (0.123–0.715)
GG 1 (1.3%) 3 (6.2%) 0.058 0.105 (0.010–1.076)
TT + TG 76 (98.7%) 45 (93.8%) / 1.00
GG 1 (1.3%) 3 (6.2%) 0.115 0.115 (0.016–1.569)
TT 60 (77.9%) 24 (50.0%) / 1.00
TG + GG 17 (22.1%) 24 (50.0%) 0.002 0.266 (0.114–0.622)
Statistically significant results in bold.
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exerts its antitumor effect. Recently, two FCGR SNPs have been
identified that affect the binding strength to IgG1, varying ADCC
function and affecting clinical tumor response [22]. In this study
no association was observed between FCGR3A rs39661 and cetux-
imab toxicity. However, rs180127 (FCGR2A H131R) was close to
being associated with skin toxicity (p = 0.051). These results show
that genotypes with the allele variant T (TT), which encodes for
histidine, could emerge as a possible predictor of reduced cetux-
imab skin toxicity (OR = 0.380 [0.144–1.003]). A putative explana-
tion could be that FCGR2A expressing macrophages would play an
important role in restoring tumor immune surveillance as pre-
dicted in preclinical models [21]. It is known that FCGR2A-131
H/H genotype has higher affinity to human IgG2 than131R allele
[19] and it is associated with longer progression-free survival in
cetuximab monotherapy. Cetuximab is a IgG1 antibody, and
131H has been related with low affinity binding to murine IgG1
[22]. Thus, in those situations IgG1 binds more strongly to FCGR2A
131R, and ADCC antitumor response can be less effective. As a
direct relationship between skin toxicity and better MAb response
has been documented [30–32], these results suggest that lower
affinity to IgG1 recognition in patients with T allele could result
in less toxicity to MAb treatment probably due to lowest antitumor
cytotoxicity.
Lastly, cyclin-D1 gene (CCDN1), a downstream effector of EGFR
is also involved in cetuximab activity. No association was observed
between the CCND1 870A > G (rs603965) polymorphism and EGFR
MoAb toxicity, an association that has been documented elsewhere
with survival in patients with colorectal cancer treated with cetux-
imab [37].Conclusions
This pilot study provides preliminary evidence supporting EGFR
rs2227983, KRAS rs61764370 and FCGR2A rs180127 as usefulbiomarkers for predicting reduced skin toxicity in HNSCC patients
receiving cetuximab-based therapy. This could indicate that
patients with these genetic variants could have less toxicity and
a poor prognosis, being better scheduled in another therapeutic
alternative. Although these polymorphisms are checked in HNSCC
cetuximab-related toxicity in this study for the first time, they
should be interpreted carefully. The statistical power of this study
is limited due to the moderate number of analyzed patients. Stud-
ies in larger groups should be performed and would be necessary
to confirm these results and validate our findings.Conflict of interest statement
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